The FDA's accelerated approval of AMTAGVI for advanced melanoma is a significant positive development for Iovance Biotherapeutics. This approval not only validates the company's research and development efforts but also opens up a new revenue stream. Given the importance of such regulatory milestones in the biotech industry, this news is likely to have a positive short-term impact on the company's stock price.